Health Canada has yet to approve generics despite applications made as far back as 2024

Health Canada has received nine applications from five named companies to sell duplicates of semaglutide, the active ingredient in Ozempic.

Danish drug maker Novo Nordisk is preparing to introduce a new version of its blockbuster drug Ozempic to compete with cheaper generics that became legal on Monday, but which are not expected to hit shelves immediately because of delays at Health Canada.

Ozempic is one of the most-prescribed drugs in Canada, with more than a million people taking it, according to Novo Nordisk. It was the highest-selling drug by revenue in the country last year.

From The Globe and Mail via this RSS feed